During the fourth quarter of 2025, the Massif Capital Real Assets Strategy advanced 9.6% net of fees, lifting full-year ...
It was agreed that many photonics technologies are both commercially viable and scalable, underpinning multiple end-user ...
GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein ...
MIAMI, FL, Jan. 06, 2026 (GLOBE NEWSWIRE) -- RenX Enterprises, Inc. ("RenX" or the "Company") (NASDAQ: RENX), formerly known as Safe and Green Development Corporation, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results